Deguelin is a natural product that displays profound antiproliferative activity. Deguelin induces apoptosis, mediated through AKT/PKB signaling pathways in malignant and premaligant human bronchial epithelia (HBE) cells, with only minimal effects on normal HBE cells. Deguelin inhibits AKT by both PI 3-kinase dependent and PI 3-kinase independent pathways. Deguelin has displayed anti-tumor lymphangiogenesis and lymphatic metastasis by down-regulation of vascular endothelial cell growth factor-D in tumor models. Deguelin has also been shown to inhibit Cox-2 expression.
1. Chun, K.H., et al. 2003. J. Natl. Cancer Inst. 95: 291-302. PMID: 12591985 2. Lee, H.Y., 2004. Biochem. Pharmacol. 68: 1119-1124. PMID: 15313408 3. Lee, H.Y., et al. 2004. Clin. Cancer Res. 10: 1074-1079. PMID: 14871987 4. Hu, J., et al. 2010. Int. J. Cancer. 127: 2455-2466. PMID: 20162567
Soluble in DMSO(25 mg/mL) and ethanol(25 mg/mL)
Store at 4° C
560.1° C at 760 mmHg (Predicted)
1.3 g/cm3 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Rated 5 out of
Hu et alHu et al. (PubMed ID 20162567) found that the tumor inhibitor, deguelin, suppressed tumor lymphangiogenesis and lymphatic metastasis via downregulation of VEGF-D in vascular endothelial cells. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn
Create a new account
Email address already exists, please enter a new valid email address.Hide
USE YOUR SOCIAL NETWORK
Create an account quickly and easily with your preferred social network account. You won't have to remember an extra name and password.
Creating an account with us makes your shopping experience much easier and faster. You can save favorites, save cart, check order status and speed through checkout with saved addresses, payment methods and more.